PL2694087T3 - Leczenie zakażenia wirusem zapalenia wątroby typu B samego lub w połączeniu z zakażeniem wirusem zapalenia wątroby typu delta i towarzyszącymi chorobami wątroby - Google Patents

Leczenie zakażenia wirusem zapalenia wątroby typu B samego lub w połączeniu z zakażeniem wirusem zapalenia wątroby typu delta i towarzyszącymi chorobami wątroby

Info

Publication number
PL2694087T3
PL2694087T3 PL12713680T PL12713680T PL2694087T3 PL 2694087 T3 PL2694087 T3 PL 2694087T3 PL 12713680 T PL12713680 T PL 12713680T PL 12713680 T PL12713680 T PL 12713680T PL 2694087 T3 PL2694087 T3 PL 2694087T3
Authority
PL
Poland
Prior art keywords
hepatitis
virus
infection
treatment
combination
Prior art date
Application number
PL12713680T
Other languages
English (en)
Inventor
Nikolai Naoumov
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2694087T3 publication Critical patent/PL2694087T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL12713680T 2011-04-01 2012-03-30 Leczenie zakażenia wirusem zapalenia wątroby typu B samego lub w połączeniu z zakażeniem wirusem zapalenia wątroby typu delta i towarzyszącymi chorobami wątroby PL2694087T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161470666P 2011-04-01 2011-04-01
EP12713680.2A EP2694087B1 (en) 2011-04-01 2012-03-30 Treatment for infection with hepatitis b virus alone or in combination with hepatitis delta virus and associated liver diseases
PCT/EP2012/055857 WO2012131061A1 (en) 2011-04-01 2012-03-30 Treatment for infection with hepatitis b virus alone or in combination with hepatitis delta virus and associated liver diseases

Publications (1)

Publication Number Publication Date
PL2694087T3 true PL2694087T3 (pl) 2015-06-30

Family

ID=45952512

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12713680T PL2694087T3 (pl) 2011-04-01 2012-03-30 Leczenie zakażenia wirusem zapalenia wątroby typu B samego lub w połączeniu z zakażeniem wirusem zapalenia wątroby typu delta i towarzyszącymi chorobami wątroby

Country Status (21)

Country Link
US (3) US20140011736A1 (pl)
EP (2) EP3006037A1 (pl)
JP (1) JP2014509630A (pl)
KR (1) KR20140010097A (pl)
CN (1) CN103458913A (pl)
AU (2) AU2012237295A1 (pl)
BR (1) BR112013024809A2 (pl)
CA (1) CA2831675A1 (pl)
CY (1) CY1116374T1 (pl)
DK (1) DK2694087T3 (pl)
ES (1) ES2533213T3 (pl)
HR (1) HRP20150430T1 (pl)
MX (1) MX2013011411A (pl)
PL (1) PL2694087T3 (pl)
PT (1) PT2694087E (pl)
RS (1) RS53911B1 (pl)
RU (1) RU2013148779A (pl)
SI (1) SI2694087T1 (pl)
SM (1) SMT201500132B (pl)
TW (1) TW201247216A (pl)
WO (1) WO2012131061A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2663322A4 (en) * 2011-01-12 2014-06-25 Scynexis Inc NEW USES OF CYCLOPHILINE INHIBITORS
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
JP2017536403A (ja) * 2014-12-04 2017-12-07 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． デルタ肝炎ウイルス感染の治療
HUE054068T2 (hu) 2015-04-21 2021-08-30 Eiger Biopharmaceuticals Inc Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények
RS61944B1 (sr) 2016-02-19 2021-07-30 Eiger Biopharmaceuticals Inc Lečenje infekcije hepatitis delta virusom sa interferonom lambda
RU2662161C1 (ru) * 2017-08-11 2018-07-24 Васильевич Иващенко Александр Ингибитор входа вируса гепатита и фармацевтическая композиция для лечения гепатита
CN113286605A (zh) * 2018-08-23 2021-08-20 艾格尔峰生物制药有限公司 用干扰素λ治疗丁型肝炎病毒感染
WO2021009333A1 (en) * 2019-07-18 2021-01-21 Enyo Pharma Synergistic effect of eyp001 and ifn for the treatment of hbv infection
IL293892A (en) * 2020-01-15 2022-08-01 Inserm Institut National De La Sant? Et De La Rech M?Dicale Use of fxr agonists for treating an infection by hepatitis d virus
CN113662945B (zh) * 2020-05-15 2024-09-27 福建广生中霖生物科技有限公司 用于治疗乙型肝炎的组合
EP4241770A1 (en) * 2020-11-05 2023-09-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceutical combination containing capsid protein inhibitor and nucleoside analog

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
JP2661044B2 (ja) * 1986-06-17 1997-10-08 カイロン コーポレイション 肝炎δの診断薬およびワクチン
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
HUT75533A (en) 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
ATE490778T1 (de) * 2004-10-01 2010-12-15 Debiopharm Sa Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion
WO2006071619A1 (en) 2004-12-23 2006-07-06 Novartis Ag Compositions for hcv treatment

Also Published As

Publication number Publication date
RU2013148779A (ru) 2015-05-10
SMT201500132B (it) 2015-07-09
PT2694087E (pt) 2015-04-09
US20140011736A1 (en) 2014-01-09
RS53911B1 (sr) 2015-08-31
HRP20150430T1 (hr) 2015-05-22
CY1116374T1 (el) 2017-02-08
HK1193571A1 (en) 2014-09-26
CN103458913A (zh) 2013-12-18
JP2014509630A (ja) 2014-04-21
TW201247216A (en) 2012-12-01
US20160101146A1 (en) 2016-04-14
KR20140010097A (ko) 2014-01-23
AU2012237295A1 (en) 2013-09-19
WO2012131061A1 (en) 2012-10-04
AU2016201888A1 (en) 2016-04-21
EP2694087A1 (en) 2014-02-12
CA2831675A1 (en) 2012-10-04
US20150023917A1 (en) 2015-01-22
MX2013011411A (es) 2014-04-14
EP2694087B1 (en) 2015-01-28
BR112013024809A2 (pt) 2016-09-06
SI2694087T1 (sl) 2015-05-29
DK2694087T3 (en) 2015-04-13
EP3006037A1 (en) 2016-04-13
ES2533213T3 (es) 2015-04-08

Similar Documents

Publication Publication Date Title
SI2694087T1 (sl) Zdravljenje zaradi infekcije z virusom hepatitisa B samim ali v kombinaciji z virusom hepatitisa delta in povezanih jetrnih obolenj
IL258450A (en) Compositions for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection
ZA201404061B (en) Compositions and methods for treating the hepatitis c virus
IL253225B (en) Sulfamoyl-arylamides and their use as drugs to treat jaundice b
IL229902B (en) Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
IL244431A0 (en) Pharmacy methods and preparations for the treatment of hepatitis b virus infection
ZA201500580B (en) 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
IL237173A0 (en) Methods for treating hepatitis b and hepatitis d infections
PL2633865T3 (pl) Zastosowanie interleukiny-22 w leczeniu wirusowego zapalenia wątroby
GB2503066B (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
ZA201205547B (en) Therapies for treating hepatitis c virus infection
IL225861A (en) Indazole-3-carboxamide derivatives and their use in the preparation of c-viral hepatitis drugs
ZA201205639B (en) Compositions and methods for treating hepatitis b virus infection
IL228725A0 (en) Treatment of hepatitis c virus infection with alisporir
IL232889A0 (en) Compounds and methods for treating hepatitis c virus
GB201116585D0 (en) Methods and uses in viral infection
HK1190604A (en) Treatment of hepatitis c virus infection with alisporivir
ZA201306878B (en) Treatment of hepatitis c virus infection with alisporivir